Natera (NTRA) said Tuesday that it has expanded its patent infringement lawsuit against NeoGenomics (NEO) related to the latter's modified version of RaDaR tests for molecular residual disease.
Natera said the District Court for the Middle District of North Carolina has granted its request to include an additional patent as part of the lawsuit.
Natera is asking the court to award it full remedies against NeoGenomics' current RaDaR test offering, including injunctive relief.
NeoGenomics did not immediately respond to a request for comment from MT Newswires.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments